2019
DOI: 10.1172/jci.insight.99485
|View full text |Cite
|
Sign up to set email alerts
|

Prior beta blocker treatment decreases leukocyte responsiveness to injury

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
22
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
9
1

Relationship

2
8

Authors

Journals

citations
Cited by 25 publications
(23 citation statements)
references
References 32 publications
1
22
0
Order By: Relevance
“…β 2 -AR agonists cause a similar reduction in TNF-α production in mononuclear cells of the peripheral blood from diabetic rats [64]. Furthermore, the chronic use of β 2 -ARselective and nonselective blockers in mice impairs the recruitment of leukocytes to the injured heart and reduces survival [65].…”
Section: Discussionmentioning
confidence: 97%
“…β 2 -AR agonists cause a similar reduction in TNF-α production in mononuclear cells of the peripheral blood from diabetic rats [64]. Furthermore, the chronic use of β 2 -ARselective and nonselective blockers in mice impairs the recruitment of leukocytes to the injured heart and reduces survival [65].…”
Section: Discussionmentioning
confidence: 97%
“…β2-ARs have been described throughout the peripheral and central nervous system. 48 50 In peripheral tissue, β2-ARs have been localized in keratinocytes, 32 , 51 myeloid cells including macrophage and dendritic cells, 52 , 53 satellite glial cells 25 and sensory neurons. 30 , 54 56 In the spinal cord, we observed β2-AR-IR on subpopulations of neurons, microglia but not astrocytes in the normal and incision rats.…”
Section: Discussionmentioning
confidence: 99%
“…β-blockers have been used successfully for decades to treat several pathologies, including hypertension, congestive heart failure, and post-MI dysfunction [21]. Moreover, chronic β-blocker treatment could alter baseline leukocyte characteristics that decrease their responsiveness to acute injury, and it means prior β-blockade may act to reduce the severity of innate immune responses [22]. Since β1AA is a weak agonist of β1AR, its accumulation might lead to the opposite effect of the blockers.…”
Section: Discussionmentioning
confidence: 99%